The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Challenges in genomic testing for lung cancer
Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, provides an overview of challenges associated with genomic testing in lung cancer, including the importance of identifying mutations for which there are treatment approaches. Dr Garcia-Pardo touches on difficulties in obtaining tissue for genomic testing, approaches to reduce turnaround times, and the use of plasma-based molecular profiling. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
